Drug Search Results
More Filters [+]

BIIB021

Alternative Names: biib021, cnf2024
Latest Update: 2024-03-04
Latest Update Note: PubMed Publication

Product Description

 BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19372565/)

Mechanisms of Action: HSP90 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BIIB021

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer|Gastrointestinal Stromal Tumors

Phase 1: Breast Cancer|Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2009-014796-51

P2

Completed

Breast Cancer

2011-10-31

120BC201

P2

Completed

Breast Cancer

2011-10-01

120BC101

P1

Completed

Breast Cancer

2011-04-01

120ST104

P1

Completed

Oncology Solid Tumor Unspecified

2010-08-01

Recent News Events